$XBIO News

Last published 1w ago

1w agoXBIOXenetic Biosciences Announces Oral Presentation at 68th ASH Annual Meeting Highlighting DNase I as a Potential Strategy to Overcome CAR T-Cell ResistanceACCESS NewswireResearch examines a self-reinforcing resistance niche created by extracellular chromatin released during CAR T-cell killing and its reversal by DNase IPresentation selected for ASH scientific session focused on
3w agoXBIOXenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell LymphomaACCESS NewswireFirst clinical evaluation of Xenetic's systemic DNase technology as an adjunct to CAR T-cell therapy in an investigator-initiated study conducted at Tel Aviv Sourasky University Medical CenterInitial efficacy data
1mo agoXBIOXenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting TherapeuticsACCESS NewswireTransaction expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on targeting neutrophil extracellular traps , a driver of disease across critical care, autoimmune disease,
3mo agoXBIOXenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase PlatformACCESS NewswireExpanded collaborative research initiatives reinforce the Company's long-term DNase development strategyOngoing generation of translational data designed to support future clinical development and deepen
5mo agoXBIOXenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell LymphomaACCESS NewswireCompany evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients in stable or progressive disease at lymphodepletion Company reported strong positive preclinical
5mo agoXBIOXenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and SurvivalACCESS NewswireNew preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignanciesData highlight potential of DNase I to improve CAR-T cell
6mo agoXBIOXenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology PlatformACCESS NewswireAdvancements across investigator-initiated studies, translational research and manufacturing activities supporting future clinical developmentStrengthened financial profile with continued royalty revenue growthEnded
6mo agoXBIOXenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual MeetingACCESS NewswireFRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 / Xenetic Biosciences, Inc. , a biopharmaceutical company focused on advancing innovative immuno-oncology technologies
8mo agoXBIOXenetic Biosciences, Inc. Reports Full Year 2025 Financial ResultsACCESS NewswireEncouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancersStrategic focus on investigator-initiated exploratory studies and institutional
11mo agoXBIOXenetic Biosciences, Inc. Announces Adjournment of 2025 Annual MeetingACCESS NewswireAdjourns 2025 Annual Meeting of StockholdersUrges Stockholders Who Have Not Voted To Get Votes In FRAMINGHAM, MA / ACCESS Newswire / December 11, 2025 / Xenetic Biosciences, Inc. ("Xenetic" or the
11mo agoXBIOXenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase PlatformACCESS NewswireFRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 / Xenetic Biosciences, Inc. , a biopharmaceutical company focused on advancing innovative immuno-oncology
12mo agoXBIOXenetic Biosciences, Inc. Reports Third Quarter 2025 Financial ResultsACCESS NewswireContinued execution on collaborations and exploratory investigator-initiated studies with institutional partnersSecured net proceeds of approximately $3.9 million from October 2025 offering FRAMINGHAM, MA / ACCESS
1y agoXBIOXenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common StockACCESS NewswireFRAMINGHAM, MA / ACCESS Newswire / October 10, 2025 / Xenetic Biosciences, Inc. , a biopharmaceutical company focused on advancing innovative immuno-oncology
1y agoXBIOXenetic Biosciences, Inc. Reports Second Quarter 2025 Financial ResultsACCESS NewswireExpanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapiesEnded the quarter with $4.8
1y agoXBIOXenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell LymphomaACCESS NewswireInvestigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / July 30, 2025 / Xenetic Biosciences, Inc.
1y agoXBIOXenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase PlatformACCESS NewswireResearch and development collaboration program to include additional models of lymphoma and leukemia to further validate DNase-I data demonstrated to date FRAMINGHAM, MA / ACCESS Newswire / July 23, 2025 / Xenetic
1y agoXBIOXenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business UpdateACCESS NewswireStrategic focus on exploratory investigator-initiated clinical studies with institutional partnersContinued progress of DNase I development program towards IND and first-in-human study for treatment of pancreatic
1y agoXBIOXenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentACCESS Newswire- Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer Spring
1y agoXBIOXenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing SarcomaACCESS NewswireInvestigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / March 26, 2025 / Xenetic Biosciences, Inc.
1y agoXBIOXenetic Biosciences, Inc. Reports Full Year 2024 Financial ResultsACCESS NewswireEncouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancersStrategic focus on exploratory investigator-initiated clinical studies with institutional
1y agoXBIOXenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic ResponsesACCESS NewswireData presented at the Society for Immunotherapy of Cancer Spring Scientific 2025 Cell Therapy MeetingFindings demonstrate that by degrading neutrophil extracellular traps , DNase I not only facilitates
1y agoXBIOXenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy MeetingACCESS NewswireFRAMINGHAM, MA / ACCESS Newswire / February 27, 2025 / Xenetic Biosciences, Inc. , a biopharmaceutical company focused on advancing innovative immuno-oncology
1y agoXBIOXenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentACCESS NewswireReid Bissonnette, Ph.D, Executive Consultant for Translational Research and Development at Xenetic, discusses extension of its Research Agreement with the University of Virginia for the advancement of its DNase-Based
1y agoXBIOXenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology PlatformACCESS NewswireCompany continuing to advance DNase-based oncology program towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / December 16, 2024 / Xenetic Biosciences, Inc.
1y agoXBIOXenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology ProgramACCESS NewswireCollaboration utilizes PeriNess' expertise in clinical development of human recombinant DNase and bolsters efforts towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / December
1y agoXBIOXenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentACCESS NewswireDr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer 39th Annual
1y agoXBIOXenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung MetastasisACCESS NewswireData presented at the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in CancerResults bolster Company's rationale for incorporating DNase I as an adjunctive
1y agoXBIOXenetic Biosciences, Inc. Reports Third Quarter 2024 Financial ResultsACCESS NewswireEstablishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indicationsOngoing progress towards first in human clinical study for locally advanced or
2y agoXBIOXenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase PlatformACCESS NewswireCompany is advancing DNase-based oncology program towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / November 7, 2024 / Xenetic Biosciences, Inc.
2y agoXBIOXenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024ACCESS NewswireFRAMINGHAM, MA / ACCESSWIRE / October 22, 2024 / Xenetic Biosciences, Inc. , a biopharmaceutical company focused on advancing innovative immuno-oncology
2y agoXBIOXenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology PlatformACCESS NewswireXenetic to supply recombinant DNase I to Tokyo Medical University for evaluation as a treatment of Ewing sarcoma in unique preclinical model FRAMINGHAM, MA / ACCESSWIRE / October 17, 2024 / Xenetic Biosciences, Inc.
2y agoXBIOXenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business UpdateACCESS NewswireOngoing preclinical studies with data expected before year endFocus on demonstration of DNase-based oncology program in clinical proof-of-concept studies in multiple indicationsEnded the quarter with $7.3 million of cash
2y agoXBIOXenetic Biosciences, Inc. Announces Executive Leadership TransitionACCESS NewswireCompany's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. ("Xenetic" or the
2y agoXBIOXenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business UpdateACCESS NewswireOngoing preclinical studies with multiple data readouts expected throughout remainder of 2024Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma
2y agoXBIOXenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology PlatformACCESS Newswire- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platformFRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 / Xenetic Biosciences, Inc.
3y agoXBIOXenetic Biosciences, Inc. Reports Third Quarter 2023 Financial ResultsACCESS NewswireEncouraging growing body of preclinical data guiding pathway to first in human trial for DNase-based oncology platformDriving development towards Phase 1 program for the treatment of pancreatic carcinoma and other
3y agoXBIOXenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO ConferenceACCESS NewswireLive moderated webcast with Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences on Tuesday, October 24th at 1:00 PM ETFRAMINGHAM, MA / ACCESSWIRE / October 11, 2023 / Xenetic Biosciences, Inc.
3y agoXBIOXenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceACCESS NewswireFRAMINGHAM, MA / ACCESSWIRE / September 5, 2023 / Xenetic Biosciences, Inc. , a biopharmaceutical company focused on advancing innovative immune-oncology
3y agoXBIOXenetic Biosciences, Inc. Reports Second Quarter 2023 Financial ResultsACCESS Newswire- Company continues to execute on plan to advance DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid
3y agoXBIOXenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight SeriesACCESS NewswireLive moderated video webcast on Wednesday, July 12th at 10:00 AM ETFRAMINGHAM, MA / ACCESSWIRE / July 5, 2023 / Xenetic Biosciences, Inc. , a
3y agoXBIOXenetic Biosciences, Inc. Announces Reverse Stock Split of Common StockACCESS NewswireFRAMINGHAM, MA / ACCESSWIRE / May 12, 2023 / Xenetic Biosciences, Inc. , a biopharmaceutical company focused on advancing innovative immune-oncology
3y agoXBIOXenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business UpdateACCESS Newswire- Continued progress with the DNase-based oncology program towards Phase 1 study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors- Ended the quarter with $12.0 million of
3y agoXBIOXenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and DevelopmentACCESS NewswireDr. Bissonnette brings over 25 years in small molecule and biotherapeutic drug discovery and development, oncology and inflammation research and regulatory expertiseFRAMINGHAM, MA / ACCESSWIRE / May 4, 2023 / Xenetic
3y agoXBIOXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. CullisonACCESS NewswireMr. Cullison brings over 20 years of experience in the pharmaceutical industry with a broad range of expertise across business development and strategic planningFRAMINGHAM, MA / ACCESSWIRE / May 3, 2023 / Xenetic
3y agoXBIOXenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase PlatformACCESS Newswire- Collaboration provides a significant step forward in the advancement of Xenetic's DNase-based oncology program towards Phase 1 clinical development- Systemic DNase program initially targeting multi-billion-dollar
3y agoXBIOXenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business UpdateACCESS Newswire- Year marked by transformational strategic license of the DNase oncology platform and shift in focus to treatment of locally advanced or metastatic solid tumors- DNase program progressing towards Phase 1 clinical
4y agoXBIOXenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory BoardACCESS NewswireFRAMINGHAM, MA / ACCESSWIRE / October 4, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announc
4y agoXBIOXenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceACCESS NewswireFRAMINGHAM, MA / ACCESSWIRE / September 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, t
4y agoXBIOXenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business UpdateACCESS NewswireSecond quarter marked by deal to in-license DNase-based oncology platform which expands pipeline with well-defined and accelerated path to clinic Advancing lead DNase program towards Phase 1 study for the treatment of pancreatic carcinoma and other loca
4y agoVNRX XBIOXenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of CancerACCESS NewswireFRAMINGHAM, MA / ACCESSWIRE / August 2, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers, and VolitionRx Limited (NYSE:VN